Table 2.
Prevention of HBV recurrence after LT with LAM and low-dose IM HBIG
| Authors | Patients (n) | DNA+ prior to LT (%) | Pretransplant LAM therapy (%) | Duration of pretransplant LAM therapy (mean mo) | DNA+ at LT (%) | Prophylactic protocol after LT | Follow-up (mean mo) | Recurrence(%) |
| Jiao et al[90] | 79 | 47 | 28 | 0.5 | 0 | LAM + HBIG IM1 | 29 | 2.5 |
| Gane et al[91] | 147 | 85 | NA | 3 | < 50 | LAM + HBIG IM2 | 61 | 4 |
| Zheng et al[77] | 114 | NA | 13 | 5 | 31 | LAM + HBIG IM3 | 16 | 14 |
| Karademir et al[92] | 35 | 51 | 40 | 6 | 14 | LAM + HBIG IM4 | 16 | 5.7 |
| Angus et al[93] | 32 | 97 | 100 | 3.2 | NA | LAM + HBIG IM5 | 18.4 | 3.1 |
NA: Not available.
1
2000 IU (IM) at LT, 800 IU (IM) daily for 6 d, weekly for 3 wk, then aim for anti-HBs > 100 IU/L;
2
800 IU (IM) at LT and daily for 6 d, then 800 IU (IM) monthly;
3
2000 IU (IM) at LT, 800 IU (IM) daily for 6 d, weekly for 3 mo, and then monthly;
4
4000 IU (IM) at LT, 2000 IU (IM) daily until anti-HBs > 200 IU/L, then aim for > 100 IU/L;
5
800 IU (IM) at LT and daily for 1 wk, then 800 IU (IM) monthly.